Mein Warenkorb

SSTR2

SSTR2 Molekülinformation

Englischer NameSomatostatin receptor 2Anzahl der inverkehr gebrachten Arzneimittel7
Anzahl der klinischen Arzneimittel27Target-AliasSomatostatin receptor type 2,SS-2-R,SS2R,SSTR2,Somatostatin Receptor 2,SRIF-1,SS2-R
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameSomatostatin receptor 2
Target-AliasSomatostatin receptor type 2,SS-2-R,SS2R,SSTR2,Somatostatin Receptor 2,SRIF-1,SS2-R
Anzahl der inverkehr gebrachten Arzneimittel7
Anzahl der klinischen Arzneimittel27
Höchste Forschungs- und EntwicklungsphaseApproved

SSTR2 Produktliste

  • Attribut

    Protein (2)Cell (1)

  • Produktbibliothek

    Online (3)

  • Spezies

    Human (3)

  • Etikett

    - (2)GFP Tag (1)

  • Marker

    Unconjugated (1)GFP Fusion (1)- (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
CHEK-ATP213
Human
HEK293
HEK293/Human SSTR2 Stable Cell Line In den Warenkorb legen
SS2-H5216
Human
HEK293
Human SSTR2 Full Length Protein (VLP) In den Warenkorb legen
SS2-HF2G3
Human
HEK293
Fluorescent Human SSTR2 Full Length Protein (VLP) In den Warenkorb legen
Gesamtmenge3
  • 1

SSTR2 Molekülhintergrund

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Somatostatin receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein coupled receptor family and have a wide expression pattern in both normal tissues and solid tumors. Investigating the function of each SSTR in several tumor types has provided a wealth of information about the common but also distinct signaling cascades that suppress tumor cell proliferation, survival and angiogenesis. This provided the rationale for developing multireceptor-targeted somatostatin analogs and combination therapies with signaling-targeted agents such as inhibitors of the mammalian (or mechanistic) target of rapamycin (mTOR). The ability of SSTR to internalize and the development of rabiolabeled somatostatin analogs have improved the diagnosis and treatment of neuroendocrine tumors.

SSTR2 Molekülalias

Smstr2,Somatostatin R2,somatostatin receptor 2,somatostatin receptor type 2,SomatostatinR2,SRIF-1,SS2R,SS-2-R,SS2-R,SST2,SSTR2

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Lutetium-177 labelled edotreotideITM-11Phase 3 ClinicalItm Solucin Gmbh, Universitaetsspitals BaselCentral Nervous System Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Stromal Tumors; Lymphoma; Neuroectodermal Tumors, Primitive, Peripheral; Neuroendocrine Carcinoma of Lung; Neuroendocrine Tumors; Pancreatic neuroendocrine tumors (pNET); Rhabdomyosarcoma; Solid tumours; Thymus Neoplasms
Details
Actinium-225 Dotate225Ac-DOTATATE; RYZ-101; [225Ac]Ac-DOTATATEPhase 3 ClinicalRayzeBio IncBreast Neoplasms; Carcinoid Tumor; Carcinoma, Neuroendocrine; Gastroenteropancreatic neuroendocrine tumor; Meningioma; Metastatic breast cancer; Multiple Myeloma; Neuroendocrine Tumors; Small Cell Lung Carcinoma
Details
Lutetium-177 DOTA satoreotideOPS-201; 177LU-OPS 201; 177Lu-DOTA- JR11; 177Lu-satoreotide; 177Lu-IPN01072; [177Lu]LuSSO110; 177Lu-IPN-1072; 177Lu SSO 110Phase 2 ClinicalOctreoPharm Sciences GmbHBreast Neoplasms; Meningioma; Pancreatic neuroendocrine tumors (pNET); Small Cell Lung Carcinoma
Details
Yttrium 90-labelled edotreotideSMT-487-[90Y]; DOTATOC-[90Y]Phase 2 ClinicalNovartis Pharma Ag, The University Of IowaAdenoma, Islet Cell; Breast Neoplasms; Carcinoid Tumor; CNS Embryonal Tumor; Lung Neoplasms; Lymphoma; Medulloblastoma; Meningioma; Neoplasms; Neuroblastoma; Neuroendocrine Tumors; Pheochromocytoma; Sarcoma; Skin Melanoma; Solid tumours
Details
ZT-01ZT 01; ZT-01Phase 2 ClinicalTulane University, University Of Toronto, Toronto, York UniversityDiabetes Mellitus, Type 1; Hypoglycemia
Details
Terbium 161 DOTATATE PRRTPhase 2 ClinicalTata Memorial CentreCarcinoma, Neuroendocrine; Neuroendocrine Tumors
Details
Al18F-NOTA-LM3Al18F-NOTA-LM3Phase 2 ClinicalPeking Union Medical College HospitalNeuroendocrine Tumors
Details
68Ga-HA-DOTATATE68Ga-HA-DOTATATEPhase 2 ClinicalUniversity Of AlbertaNeuroendocrine Tumors
Details
Re-188 P 2045Rhenium-188 P2045; Rhenium-188-P-2045; Re-188 P 2045; Rh-188 P2045; Rhenium 188 P2045; P2045; BAY-865284Phase 2 ClinicalBayer AGCarcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Lung Neoplasms; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Small Cell Lung Carcinoma
Details
CRN-09682CRN-09682; CRN09682Phase 2 ClinicalCrinetics Pharmaceuticals IncCarcinoma, Neuroendocrine; Neuroendocrine Tumors
Details
MB-0151Phase 2 ClinicalMainline Biosciences (Shanghai) Co Ltd, Zhongshan Zhuliuyuan Biotechnology Co LtdSolid tumours
Details
177Lu-LNC1010177Lu-LNC1010Phase 2 ClinicalYantai Lannacheng Biotechnology Co LtdNeoplasms; Neuroendocrine Tumors; Pancreatic neuroendocrine tumors (pNET); Solid tumours
Details
[203-Pb] VMT-NET[203-Pb] VMT-NETPhase 2 ClinicalPerspective Therapeutics IncCarcinoma, Renal Cell; Head and Neck Neoplasms; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Small Cell Lung Carcinoma
Details
64Cu-SarTatePhase 2 ClinicalClarity Pharmaceuticals Ltd, University Of MelbourneNeuroendocrine Tumors
Details
Gallium-68 satoreotide68Ga-DOTA-JR11; 68Ga-SSO-120; 68Ga IPN-1070; 68Ga-OPS-202Phase 1 ClinicalIpsen IncBreast Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma
Details
68Ga-NOTA-3PTATE-RGD68Ga-NOTA-3P-TATE-RGD; 68Ga-NOTA-3PTATE-RGDPhase 1 ClinicalPeking Union Medical College HospitalCarcinoma, Neuroendocrine; Lung Neoplasms; Meningioma; Neuroendocrine Tumors
Details
[68Ga]Ga-FL-031Phase 1 ClinicalFull Life Technologies LtdNeoplasms
Details
NTQ-6179NTQ-6179Phase 1 ClinicalNanjing Zhengda Tianqing Pharmaceutical Co LtdAcromegaly; Neuroendocrine Tumors
Details
68Ga-DOTA-LM368Ga-DOTA-LM3Phase 1 ClinicalPeking Union Medical CollegeNeuroendocrine Tumors
Details
68Ga-NODAGA-LM368Ga-NODAGA-LM3Phase 1 ClinicalPeking Union Medical CollegeNeuroendocrine Tumors
Details
177Lu-DOTA-LM3177Lu-DOTA-LM3Phase 1 ClinicalZentralklinik Bad BerkaNeuroendocrine Tumors
Details
177Lu-TATE-RGD177Lu-TATE-RGDPhase 1 ClinicalPeking Union Medical College HospitalNeoplasms
Details
[99mTc]Tc-TECANT1Phase 1 ClinicalJagiellonian University Sylff Fellows Association, Ljubljana University Medical Centre, Medical University Of Innsbruck, Narodowe Centrum Badan JadrowychNeuroendocrine Tumors
Details
161Tb-DOTA-LM3161Tb-DOTA-LM3Phase 1 ClinicalUniversity Hospital BaselGastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors
Details
44Sc-edotreotideSc44-DOTATOC; 44Sc-DOTA-[3-Tyr]-octreotide; 44Sc-edotreotideClinicalZentralklinik Bad BerkaDiagnostic agents
Details
68Ga-FAPI-LM368Ga-FAPI-LM3ClinicalThe First Affiliated Hospital Of Xiamen UniversityAdenomatous Polyposis Coli
Details
225AcDOTA-LM3225AcDOTA-LM3ClinicalCURANOSTICUM Wiesbaden-FrankfurtPancreatic neuroendocrine tumors (pNET)
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Pasireotide PamoateApprovedNovartis Pharma AgSignifor larUnited StatesAcromegalyRecordati Rare Diseases Inc2014-12-15Acromegaly; Carcinoid Tumor; Cushing Syndrome; Gigantism; Meningioma; Neuroendocrine Tumors; Pituitary ACTH Hypersecretion
Details
Lutetium (177Lu) oxodotreotideLu-DOTATATE; 177Lu-DOTATATE; [Lu-177]-DOTATATE; AAA-601; F-1515; XTR-008; [177Lu]Lu-DOTA-TATE; Lutetium (177Lu) DOTA-TATEApprovedAdvanced Accelerator Applications SaLutatheraEUNeuroendocrine TumorsAdvanced Accelerator Applications Sa2017-09-26Adenoma, Islet Cell; Breast Neoplasms; Bronchial Neoplasms; Carcinoid Heart Disease; Carcinoma, Neuroendocrine; Gastroenteropancreatic neuroendocrine tumor; Leiomyosarcoma; Liver Neoplasms; Malignant Carcinoid Syndrome; Medullary thyroid cancer (MTC); Meningioma; Metastatic breast cancer; Neuroblastoma; Neuroendocrine Carcinoma of Lung; Neuroendocrine Tumors; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Paraganglioma; Pheochromocytoma; Pituitary Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma
Details
PaltusotineCRN-00808ApprovedCrinetics Pharmaceuticals IncPALSONIFYUnited StatesAcromegalyCrinetics Pharmaceuticals Inc2025-09-25Acromegaly; Carcinoid Tumor; Cecal Neoplasms; Diarrhea; Ileal Neoplasms; Intestinal Neoplasms; Liver Neoplasms; Malignant Carcinoid Syndrome; Neuroendocrine Tumors; Pancreatic Neoplasms
Details
Vapreotide AcetateRC-160; BMY-41606ApprovedDebiopharm GroupSanvar, Docrised, Sanvar IR, Sanvar SRAcromegaly; Crohn Disease; Diarrhea; Esophageal and Gastric Varices; Hemorrhage; Hypertension, Portal; Intraoperative Complications; Neuroendocrine Tumors; Pancreatic Neoplasms; Postoperative Complications
Details
Pasireotide DiaspartateSOM-230; SOM-230C; SOM-320ApprovedNovartis Pharma AgSignifor, 丝尼芬EUCushing SyndromeRecordati Rare Diseases Inc2012-04-24Acromegaly; ACTH Syndrome, Ectopic; Adenoma, Islet Cell; Alcoholism; Carcinoid Tumor; Carcinoma, Hepatocellular; Cluster Headache; Congenital Hyperinsulinism; Cushing Syndrome; Cysts; Dumping Syndrome; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Neoplasms; Hormone-Resistant Prostate Neoplasms; Hyperinsulinism; Hypoglycemia; Insulinoma; Liver Cirrhosis; Medullary thyroid cancer (MTC); Meningioma; Multiple Myeloma; Nelson Syndrome; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Post-bariatric Hypoglycemia; Prolactinoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Small Cell Lung Carcinoma; Thymoma; Thyroid Neoplasms; Uveal melanoma
Details
Ga-68 EdotreotideSMT-487; [68Ga]DOTATOC; 68Ga-DOTATOCApprovedAdvanced Accelerator Applications SaSomaKit TOC, Gallium Dotatoc Ga 68, TOCscanEUDiagnostic agents; Neuroendocrine Tumors; Pancreatic neuroendocrine tumors (pNET)Advanced Accelerator Applications Sa2016-12-08Breast Neoplasms; Carcinoid Tumor; Carcinoma, Neuroendocrine; Diagnostic agents; Medulloblastoma; Meningioma; Multiple Endocrine Neoplasia Type 1; Nasopharyngeal Carcinoma; Neuroblastoma; Neuroendocrine Tumors; Pancreatic neuroendocrine tumors (pNET); Paraganglioma; Pituitary Neoplasms; Solid tumours; Somatostatinoma; von Hippel-Lindau Disease
Details
Gallium (68Ga) oxodotreotide68Ga-DOTA-TATE; 68-Ga-DOTA-TATE; AAA-501ApprovedAdvanced Accelerator Applications SaNetspotUnited StatesNeuroendocrine TumorsAaa Usa Inc2016-06-01Carcinoid Tumor; Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Pancreatic Neoplasms; Paraganglioma; Pheochromocytoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thyroid Neoplasms; von Hippel-Lindau Disease
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns